Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
Menu
My View
  • Edit
  • Add your favourite topics for quick access
Meet the Team
Ask the Analyst
Partnered Content
PDF Library
RSS Feeds
Subscribe
FAQs
Advertising
Report Store
UsernamePublicRestriction
Tags:
BioPharmaceutical

MGI Pharma Boosts Hematology Pipeline With AkaRx Agreement

This article was originally published in The Pink Sheet Daily

  • News

Executive Summary

Phase II thrombocytopenia candidate AKR-501 has revenue potential in excess of $1 billion in the U.S., MGI says.

You may also be interested in...



Sale Speculation Begins As MGI Pharma Considers ‘Strategic Alternatives’

Carl Icahn’s recent purchase of more than 600,000 shares feeds the rumor mill.

Sale Speculation Begins As MGI Pharma Considers ‘Strategic Alternatives’

Carl Icahn’s recent purchase of more than 600,000 shares feeds the rumor mill.

MGI Pharma Files Aquavan NDA

Drug for mild to moderate sedation could achieve peak sales of $400 million, company tells "The Pink Sheet" DAILY.

Table

View full table

Related Content

Pink Sheet
Pink Sheet

Topics

Tags:
BioPharmaceutical
UsernamePublicRestriction

Register

LL043624

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By